StoneX Group’s Citius Pharmaceuticals CTXR Stock Holding History

StoneX Group’s Portfolio CTXR Stock Details CTXR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-444	Closed	-$8.77K	–	493
2022 Q4	$8.77K	Buy	+444	New	+$12.1K	﹤0.01%	456

Other funds holding CTXR

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

StoneX Group's CTXR Position: Q1 2023 in Review

StoneX Group sold out of Citius Pharmaceuticals (CTXR) in Q1 2023, closing a stake of 444 shares — an estimated $8.77K sold.

StoneX Group first reported a position in CTXR in Q4 2022 and held it in 1 quarter. The position peaked at $8.77K in Q4 2022. 55 funds tracked by Wall St. Rank hold CTXR as of Q1 2023.

StoneX Group reported no remaining Citius Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
StoneX Group sold 444 Citius Pharmaceuticals shares in Q1 2023, an estimated $8.77K.
StoneX Group first reported a position in Citius Pharmaceuticals in Q4 2022 and held it in 1 quarter.
StoneX Group's Citius Pharmaceuticals position peaked at $8.77K in Q4 2022.
55 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q1 2023.

Based on StoneX Group's 13F filing for Q1 2023, filed 11 May 2023.